Study #2022-0351
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours (TROPION-PanTumor03).
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-559-2966
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.